CompletedPhase 2NCT00004747

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis

Studying Cystic fibrosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Center for Research Resources (NCRR)
Principal Investigator
Preston W. Campbell, M.d
Vanderbilt University Medical Center
Intervention
mucoid exopolysaccharide P. aeruginosa immune globulin IV(drug)
Enrollment
170 enrolled
Eligibility
6 years · All sexes
Timeline
1995

Collaborators

Vanderbilt University Medical Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00004747 on ClinicalTrials.gov

Other trials for Cystic fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Cystic fibrosis

← Back to all trials